Skip to main content

Table 2 Clinical and laboratorial data of sample before and after the therapeutic intervention, separated by gender.

From: Effect of the carbohydrate counting method on glycemic control in patients with type 1 diabetes

Variables Men   Women  
  Baseline 3 months Significance
Level
(p)
Baseline 3 months Significance
level
(p)
n (number) 19 19   32 32  
Duration of diabetes (years) 9,24 ± 1,41 9,24 ± 1,41 0,124 12,34 ± 1,48 12,34 ± 1,48 0,167
   BMI (kg/m2) 22,55 ± 0,62 22,88 ± 0,65 0,37 23,0 ± 0,57 23,0 ± 0,65 0,47
   sBP (mmHg) 120 ± 0,75 110 ± 1,78 0,58 100,82 ± 0,29 110 ± 0,38 0,33
   sDP(mmHg) 70,67 ± 1,23 70,75 ± 1,28   60,95 ± 1,04 90,59 ± 12,40  
A1c (%) 10,28 ± 0,55 9,30 ± 0,50 0,01 10,00 ± 2,42 9,65 ± 2,45 0,00
Cholesterol(mg/dl) 159,63 ± 6,37 163,73 ± 5,70 0,164 183 ± 7,69 179,56 0,48
HDL- Cholesterol(mg/dl) 50,63 ± 3,63 49,18 ± 4,07 0,46 55,7 ± 2,19 55,90 ± 1,77 0,92
LDL- Cholesterol
(mg/dl)
193,71 ± 7,86 184,41 ± 6,13 0,13 220,59 ± 8,00 213,59 ± 6,13 0,32
Triglycerides (mg/dl) 89,73 ± 11,18 96,68 ± 14,25 0,49 95,31 ± 10,2 109 ± 14,15 0,09
Fasting blood sugar- (mg/dl) 153,84 ± 28,37 153,84 ± 28,37 0,74 200,34 ± 20,32 171,12 ± 18,85 0,25
Postprandial glycemia (mg/dl) 213,05 ± 16,83 231,47 ± 20,64 0,46 282 ± 16,32 250,46 ± 22,44 0,19
Insulin dose/kg 0,89 ± 0,31 1,05 ± 0,31 0,00 1,07 ± 0,53 1,13 ± 0,49 0,10
NPH insulin dose 55,22 ± 19,90 56,89 ± 18,52 0,16 55,00 ± 23,91 54,22 ± 22,65 0,40
Rapid insulin dose 3,65 ± 5,30 3,12 ± 2,34 0,67 4,84 ± 10,17 12,13 ± 7,77 0,00